Artemisinin Combination Therapy (ACT) Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, Other), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Drug Stores & Retail Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Artemisinin Combination Therapy (ACT) Market Size & Growth Analysis

The global artemisinin combination therapy market size was valued at USD 680.15 million in 2025 and is projected to grow from USD 736.94 million in 2026 to USD 1399.80 million by 2034, registering a CAGR of 8.35% during the forecast period from 2026 to 2034. North America dominated the artemisinin combination therapy market with a market share of 40.17% in 2025.

The artemisinin combination therapy market encompasses a range of pharmaceutical formulations designed for the treatment of malaria through the synergistic use of artemisinin derivatives and partner drugs. The market includes various combination types such as Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, and other formulations aimed at improving therapeutic efficacy and minimising drug resistance. These therapies are distributed through multiple channels, including hospital pharmacies, online pharmacies, and drug stores & retail pharmacies, ensuring broad accessibility across both public and private healthcare systems globally.

Type Insights

The Artemether + Lumefantrine segment dominated the artemisinin combination therapy market with a revenue share of 38.23%, primarily due to its widespread adoption as a first-line treatment for uncomplicated Plasmodium falciparum malaria across Africa and Asia-Pacific. Its proven efficacy, WHO prequalification, and inclusion in national malaria control guidelines have contributed to its leading market share.

The Dihydroartemisinin + Piperaquine segment is anticipated to register the fastest CAGR of 9.26% during the forecast period. This growth is driven by its extended post-treatment prophylactic effect, favorable safety profile, and increasing preference in Southeast Asia and parts of Africa to counter rising resistance to older ACT combinations.

Request Customizationto receive a tailored report.

Distribution Channel Insights

The Hospital Pharmacies segment dominated the market in 2025 with a revenue share of 48.52%, owing to the high volume of ACT prescriptions for in-patient and severe malaria cases. Hospitals play a critical role in administering ACTs under clinical supervision, especially in regions with established healthcare infrastructures such as urban Africa and Southeast Asia.

The Online Pharmacies segment is expected to exhibit the fastest CAGR of 9.82% during the forecast period, driven by the increasing digitalization of healthcare, improved logistics for temperature-stable formulations, and expanding e-pharmacy networks in emerging economies such as India, Kenya, and Nigeria.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North America region accounted for a major share of 40.17% in the artemisinin combination therapy market in 2025. The region’s growth is driven by strong participation in malaria research, formulation development, and international health partnerships aimed at combating drug-resistant malaria strains.

Canada’s artemisinin combination therapy market growth is driven by the expansion of biopharmaceutical collaborations focusing on synthetic artemisinin production technologies. The country’s emphasis on sustainable biomanufacturing processes and academic industry partnerships is strengthening its role in supplying high-quality APIs to malaria-endemic nations.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

Asia Pacific is emerging as the fastest-growing region in the artemisinin combination therapy market with a CAGR of 10.34%, supported by its dominant position in raw material production and pharmaceutical exports. Countries such as China, India, and Vietnam are leading in Artemisia annua cultivation and downstream synthesis of artemisinin derivatives, ensuring cost-efficient and large-scale production capacity.

India’s artemisinin combination therapy market is witnessing strong momentum due to the government’s National Framework for Malaria Elimination (NFME) and increasing domestic manufacturing under the “Make in India” initiative. The country’s potent generic pharmaceutical sector, combined with local distribution networks targeting rural endemic zones, is accelerating the adoption of affordable ACT treatments nationwide.

Europe Market Insights

Europe is experiencing consistent growth in the artemisinin combination therapy market, supported by strong R&D capabilities, stringent quality standards, and strategic involvement in international health initiatives. European pharmaceutical companies are investing heavily in the development of next-generation ACTs to address resistance issues and optimize treatment outcomes for pediatric and pregnant populations.

France’s artemisinin combination therapy market growth is propelled by active participation in global procurement programs such as the Global Fund and Unitaid. The presence of advanced drug formulation facilities and ongoing government support for malaria research initiatives are enhancing France’s role as a key exporter of high-quality ACT formulations.

Latin America Market Insights

The Latin America artemisinin combination therapy market is expanding steadily, driven by targeted malaria elimination programs and increasing regional funding for disease surveillance. Countries such as Brazil, Peru, and Colombia are enhancing access to ACTs through integrated healthcare systems and region-specific treatment campaigns aimed at reducing transmission in border areas.

Brazil’s artemisinin combination therapy market growth is influenced by local production of antimalarial medicines through public-private partnerships between Fiocruz and international health agencies. The country’s implementation of digital disease-tracking platforms and improved medicine procurement processes is supporting efficient ACT deployment in high burden regions.

Middle East and Africa Market Insights

The market in the Middle East and Africa region is driven by extensive donor funding and national-scale treatment programs. Expanding access through community-based distribution systems and widespread use of WHO-prequalified ACT brands are ensuring broad treatment coverage across endemic countries.

South Africa’s artemisinin combination therapy market is growing due to government-led malaria control strategies focused on cross-border collaboration with Mozambique and Eswatini. The establishment of regional pharmaceutical manufacturing hubs and training initiatives for healthcare workers is improving ACT availability and strengthening the country’s public health infrastructure.

Competitive Landscape

The global artemisinin combination therapy market is moderately fragmented, comprising a mix of established pharmaceutical manufacturers, biotechnology innovators, and regional producers focused on the development, extraction, and synthesis of artemisinin derivatives and combination therapies.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: An emerging market player

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a global innovation-driven pharmaceutical and healthcare enterprise headquartered in China, is emerging as a key player in the artemisinin combination therapy market. The company is focused on improving access to affordable and high-quality antimalarial treatments across Africa and other malaria-endemic regions through its diversified product portfolio and strategic regional investments.

• In April 2024, Shanghai Fosun Pharmaceutical（Group）, Ltd., expanded its malaria treatment portfolio by introducing its self-developed artesunate injection (Argesun), which reduced preparation time from three minutes to one minute and standardized concentration for both intravenous and intramuscular administration, enhancing treatment safety, dosing precision, and clinical convenience. This innovation strengthened the company’s position in the market and reinforced its commitment to improving therapeutic outcomes in global malaria control programs.

List of Key and Emerging Players in Artemisinin Combination Therapy (ACT) Market